Company news

MacroGenics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

MacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial Results

May 8, 2023

MacroGenics Announces Date of First Quarter 2023 Financial Results Conference Call

May 3, 2023

MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)

March 21, 2023

MacroGenics Provides Corporate Update and 2022 Financial Results

March 14, 2023

MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million

March 7, 2023

MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call

March 6, 2023

MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium

February 12, 2023

MacroGenics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023

MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors

January 3, 2023

MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab

November 16, 2022

MacroGenics Provides Corporate Update and Third Quarter 2022 Financial Results

November 2, 2022

MacroGenics Announces Date of Third Quarter 2022 Financial Results Conference Call

October 25, 2022

Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies

October 16, 2022

MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results

August 7, 2022

MacroGenics Announces Date of Second Quarter 2022 Financial Results Conference Call

July 24, 2022

MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer

July 7, 2022

MacroGenics Announces Appointment of William Heiden to Board of Directors

May 22, 2022

MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results

May 2, 2022

MacroGenics Announces Date of First Quarter 2022 Financial Results Conference Call

April 24, 2022

MacroGenics Announces Executive Promotion

February 27, 2022

MacroGenics Provides Update on Corporate Progress and 2021 Financial Results

February 23, 2022

MacroGenics Announces Date of Fourth Quarter 2021 Financial Results Conference Call

February 13, 2022

I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors

December 26, 2021

MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Results

November 1, 2021

MacroGenics Announces Date of Third Quarter 2021 Financial Results Conference Call

October 25, 2021

MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presented at ESMO 2021 Virtual Annual Congress

September 15, 2021

MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021

September 15, 2021

MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress

September 11, 2021

MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA™ in Patients with HER2-Positive Metastatic Breast Cancer

September 6, 2021

MacroGenics Provides Update on Corporate Progress and Second Quarter 2021 Financial Results

July 28, 2021

MacroGenics Announces Date of Second Quarter 2021 Financial Results Conference Call

July 21, 2021

Zai Lab and MacroGenics Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology

June 15, 2021

MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology

June 15, 2021

MacroGenics Announces Preliminary Clinical Results from Phase 1 Study of MGC018 to be Presented at ASCO Annual Meeting

May 18, 2021

MacroGenics Provides Update on Corporate Progress and First Quarter 2021 Financial Results

April 28, 2021

MacroGenics Announces Date of First Quarter 2021 Financial Results Conference Call

April 18, 2021

Alligator Bioscience and MacroGenics Enter into a Research Collaboration to Develop a Novel Immunotherapy

April 14, 2021

MacroGenics Announces Presentations at the 2021 AACR Annual Meeting

April 9, 2021

MacroGenics Provides Update on Corporate Progress and 2020 Financial Results

February 24, 2021

MacroGenics Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call

February 17, 2021

MacroGenics Names Federica O’Brien to its Board of Directors

February 10, 2021

MacroGenics Announces Achievement of $10 Million Milestone Related to Retifanlimab Collaboration with Incyte

February 10, 2021

MacroGenics Announces Publication of SOPHIA Trial Results for MARGENZA™ in JAMA Oncology

January 24, 2021

MacroGenics Announces MGD019 Publication in Cell Reports Medicine

December 21, 2020

MacroGenics Enters Research Collaboration with Janssen to Develop Novel DART® Molecule

December 17, 2020

MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer

December 15, 2020

MacroGenics Announces Achievement of $25 Million in Milestones Related to Retifanlimab Collaboration with Incyte

November 29, 2020

MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab

November 29, 2020

MacroGenics Provides Update on Corporate Progress and Third Quarter 2020 Financial Results

November 3, 2020

MacroGenics Announces Flotetuzumab and Tebotelimab Presentations at the ASH Annual Meeting 2020

November 3, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 8 decks. Every deck is listed under its year.